Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.

Supachaya SriphoosanaphanWitthawat PantumongkolWantanee KulpengChanchai CharonpongsuntornTawesak TanwandeeWattana SukeepaisarnjaroenAbhasnee Sobhonslidsuk Pisit Tangkijvanich

Published in: PloS one (2024)

Although A+B yielded the highest clinical benefit compared with BSC for the treatment of uHCC patients, A+B is not cost-effective in Thailand at the current price and poses budgetary challenges.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
radiation therapy
combination therapy